Opportunities this week:
- Apple (Overweight PT $290 +7.4% upside): Reiteration of new Overweight rating following Q1 results.
- Novo Nordisk (Overweight PT DKK 422 13% upside): CagriSema drug trial update, and Q4 preview with PT change from DKK451 to DKK422.
- Kerry Group (Overweight PT: €111.69 +50% Upside): Reinstate investment case ahead of FY25 results.